Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.005
+0.005 (0.13%)
Mar 31, 2025, 10:49 AM EDT - Market open
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 7.00, with a low estimate of 6.00 and a high estimate of 8.00. The average target predicts an increase of 74.78% from the current stock price of 4.01.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytek Biosciences stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stephens & Co. | Stephens & Co. | Buy Reiterates $6 | Buy | Reiterates | $6 | +49.81% | Mar 19, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +99.75% | Mar 4, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $8 → $8.5 | Buy | Maintains | $8 → $8.5 | +112.23% | Nov 11, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $8.5 → $8 | Buy | Maintains | $8.5 → $8 | +99.75% | Aug 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8.5 | Buy | Maintains | $10 → $8.5 | +112.23% | May 13, 2024 |
Financial Forecast
Revenue This Year
213.80M
from 200.45M
Increased by 6.66%
Revenue Next Year
234.19M
from 213.80M
Increased by 9.54%
EPS This Year
-0.05
from -0.05
EPS Next Year
0.01
from -0.05
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 235.8M | 265.3M | 303.1M |
| Avg | 213.8M | 234.2M | 267.3M |
| Low | 200.3M | 211.3M | 228.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 17.6% | 24.1% | 29.4% |
| Avg | 6.7% | 9.5% | 14.2% |
| Low | -0.1% | -1.2% | -2.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.02 | 0.13 | 0.19 |
| Avg | -0.05 | 0.01 | 0.08 |
| Low | -0.07 | -0.07 | 0.01 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 1,752.9% |
| Avg | - | - | 700.0% |
| Low | - | - | -3.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.